10,257 results match your criteria Factor X


Coagulation signaling and cancer immunotherapy.

Thromb Res 2020 Jul;191 Suppl 1:S106-S111

Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany.

The last decades have delineated many interactions of the hemostatic system with cancer cells that are pivotal for cancer-associated thrombosis, angiogenesis and metastasis. Expanding evidence shows that platelets, the tissue factor pathway, and proteolytic signaling involving protease-activated receptors (PARs) are also central players in innate and adaptive immunity. Recent studies in immune-competent mice have uncovered new immune-evasive roles of coagulation signaling networks in the development and growth of different preclinical tumor models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0049-3848(20)30406-0DOI Listing

Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation.

Blood 2020 Jul 28. Epub 2020 Jul 28.

fRoald Dahl Haemostasis & Thrombosis Centre, Royal Liverpool University Hospital, Liverpool L7 8XP, UK., United Kingdom.

Thrombin generation is pivotal to both physiological blood clot formation and pathological development of disseminated intravascular coagulation (DIC). In critical illness, extensive cell damage can release histones into the circulation, which can increase thrombin generation and cause DIC, but the molecular mechanism is not clear. Typically, thrombin is generated by the prothrombinase complex, comprising activated factor X (FXa), activated co-factor V (FVa) and phospholipids to cleave prothrombin in the presence of calcium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019002973DOI Listing
July 2020
10.452 Impact Factor

Effect of chemical aging of aqueous organic aerosols on the rate of their steady-state nucleation.

Phys Chem Chem Phys 2020 Jul 28. Epub 2020 Jul 28.

Department of Chemical and Biological Engineering, SUNY at Buffalo, Buffalo, New York 14260, USA.

We present the steady-state solution of the kinetic equation for the size and composition distribution of an ensemble of aqueous organic droplets, evolving via nucleation and concomitant chemical aging. The partial differential equation of second order for the temporal evolution of this distribution can be reduced to the canonical form of the multidimensional Fokker-Planck equation, which can be solved analytically by using the method of complete separation of variables. Its solution for the steady-state process provides the stationary distribution of droplets in the vicinity of the saddle point of the free-energy surface as well as the stationary nucleation rate in the form of the product "kinetic (Zeldovich) factor × normalization factor × exp(-free energy of nucleus formation)". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/d0cp02592eDOI Listing

Deciphering the coagulation profile through the dynamics of thrombin activity.

Sci Rep 2020 Jul 27;10(1):12544. Epub 2020 Jul 27.

Synapse Research Institute, Pastoor Habetsstraat 50, 6217 KM, Maastricht, The Netherlands.

Thrombosis has proven to be extremely difficult to predict. Measuring the generation of thrombin is a very sensitive method to detect changes in the hemostatic system. We developed a method based on the generation of thrombin to further fingerprint hemostasis, which we have named thrombin dynamics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-69415-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385119PMC

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Thromb Haemost 2020 Jul 27. Epub 2020 Jul 27.

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Hemophilia A, characterized by absent or ineffective coagulation factor VIII (FVIII), is a serious bleeding disorder that entails severe and potentially life-threatening bleeding events. Current standard therapy still involves replacement of FVIII, but is often complicated by the occurrence of neutralizing alloantibodies (inhibitors). Management of patients with inhibitors is challenging and necessitates immune tolerance induction for inhibitor eradication and the use of bypassing agents (activated prothrombin complex concentrates or recombinant activated factor VII), which are expensive and not always effective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0040-1714279DOI Listing

Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.

Acta Haematol 2020 Jul 22:1-4. Epub 2020 Jul 22.

Department of Hematology and Oncology, Nagano Children's Hospital, Azumino, Japan,

Treating patients with hemophilia and inhibitors is often problematic. The presence of inhibitors negatively impacts the effectiveness of treatment to achieve hemostasis especially in patients with hemophilia B, owing mainly to allergic reactions to factor IX (FIX) concentrates and the low success rate of immune tolerance therapy. A 9-month-old boy had intracranial hemorrhage and was diagnosed with hemophilia B. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508722DOI Listing

Physiological characteristics associated with increased resistance to decompression sickness in male and female rats.

J Appl Physiol (1985) 2020 Jul 23. Epub 2020 Jul 23.

Université de Brest.

Decompression sickness (DCS) is a complex and poorly understood systemic disease with wide inter-individual resistance variability. We selectively bred rats with a 3-fold greater resistance to DCS than standard ones. To investigate possible physiological mechanisms underlying the resistance to DCS, including sex-related differences in these mechanisms, 15 males and 15 females resistant to DCS were compared with aged-matched standard Wistar males (n=15) and females (n=15). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/japplphysiol.00324.2020DOI Listing

Paroxysmal atrial fibrillation is associated with early coagulation activity regardless of risk factors for embolism.

Minerva Cardioangiol 2020 Jul 10. Epub 2020 Jul 10.

Section of Cardiology, Department of Cardiology, Second City Hospital of Sofia, Sofia, Bulgaria.

Background: Paroxysmal atrial fibrillation (PAF) is associated with an increased incidence of embolic events, even in patients with no embologenic risk factors. This fact raises the question for the hypercoagulability in PAF as a state closely related to the arrhythmia itself, independent of other well established embologenic risk factors. The scarce data on that topic predisposed our aim that was to study coagulation activity in the early hours (up to the twenty-fourth hour) of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0026-4725.20.05209-3DOI Listing

How Much Is the Inevitable Loss of Different Coagulation Factors During Blood Product-Free Liver Transplantations?

Transplant Proc 2020 Jul 8. Epub 2020 Jul 8.

Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary.

Background: Bloodless liver transplantations (LT) have already been reported, but special characteristics of hemostatic changes remain less defined. The aim of this study was to evaluate the "inevitable" loss of coagulation factors (CF) in blood product-free LT.

Methods: Blood product and CF concentrate-free LT patient data were analyzed in terms of the first 2 days of perioperative hemostasis kinetics (N = 59). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2020.05.006DOI Listing

MHC class I transactivator NLRC5 in host immunity, cancer and beyond.

Immunology 2020 Jul 7. Epub 2020 Jul 7.

Department of Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

The presentation of antigenic peptides by major histocompatibility complex (MHC) class I and class II molecules is crucial for activation of the adaptive immune system. The nucleotide-binding domain and leucine-rich repeat receptor family members CIITA and NLRC5 function as the major transcriptional activators of MHC class II and class I gene expression, respectively. Since the identification of NLRC5 as the master regulator of MHC class I and class-I-related genes, there have been major advances in understanding the function of NLRC5 in infectious diseases and cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imm.13235DOI Listing

Use of plasma-derived factor X concentrate in neonates and infants with congenital factor X deficiency.

J Thromb Haemost 2020 Jul 2. Epub 2020 Jul 2.

Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, Georgia, USA.

Background: Congenital factor X deficiency (FXD) is a rare bleeding disorder that often presents with severe bleeding in the neonatal period. Long-term prophylaxis with infusions of FX-containing products is recommended in patients with FXD and a personal or family history of severe bleeding. A plasma-derived FX concentrate (pdFX) is approved for on-demand and prophylactic therapy in adults and children with FXD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14985DOI Listing

Procoagulant Activities of Skeletal and Cardiac Muscle Myosin depend on contaminating phospholipid.

Blood 2020 Jun 30. Epub 2020 Jun 30.

Harvard Medical School, United States.

Recent reports indicate that suspended skeletal and cardiac myosin, such as might be released during injury, can act as procoagulants by providing membrane-like support for factors Xa and Va in the prothrombinase complex. Further, skeletal myosin provides membrane-like support for activated protein C. This raises the question of whether purified muscle myosins retain procoagulant phospholipid through purification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005930DOI Listing

A Compound Heterozygosis of Two Novel Mutations Causes Factor X Deficiency in a Chinese Pedigree.

Acta Haematol 2020 Jun 29:1-6. Epub 2020 Jun 29.

Medical Laboratory Center, First Medical Center of Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China,

Background: Mutations in the F10-coding gene can cause factor X (FX) deficiency, leading to abnormal coagulation activity and severe tendency for hemorrhage. Therefore, identifying mutations in F10 is important for diagnosing congenital FX deficiency.

Methods: We studied a 63-year-old male patient with FX deficiency and 10 of his family members. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507689DOI Listing

Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.

Sci Rep 2020 Jun 25;10(1):10391. Epub 2020 Jun 25.

Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.

MYC-associated factor X (MAX) is a protein in the basic helix-loop-helix leucine zipper family, which is ubiquitously and constitutively expressed in various normal tissues and tumors. MAX protein mediates various cellular functions such as proliferation, differentiation, and apoptosis through the MYC-MAX protein complex. Recently, it has been reported that MYC regulates the proliferation of anaplastic large cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67500-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316730PMC

Numerical Simulation of Mass-Transfer Characteristics of a Bubble Rising in Yield Stress Fluids.

ACS Omega 2020 Jun 2;5(23):13878-13885. Epub 2020 Jun 2.

College of Energy and Environment, Shenyang Aerospace University, Shenyang, Liaoning 110136, China.

The mass-transfer characteristics of bubbles rising in yield stress fluids was investigated numerically using volume-of-fluid and user-defined function methods in this study. The CO concentration profiles inside the liquid phase near the bubble equator at different bubble diameters, yield stresses, consistency coefficients, and flow indices were observed. The results revealed that the rate of mass transfer decreased with the increase of yield stress, consistency coefficient, and flow index of the liquid phase and the decrease of bubble diameter. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsomega.0c01265DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301553PMC

Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia.

Authors:
Midori Shima

Res Pract Thromb Haemost 2020 May 28;4(4):446-454. Epub 2020 Apr 28.

Thrombosis and Hemostasis Research Center Nara Medical University Kashihara City Nara Japan.

Regular prophylaxis has markedly improved the treatment for patients with hemophilia A, especially after the introduction of highly purified factor VIII (FVIII) concentrates. However, frequent intravenous infusions and the development of FVIII inhibitors remain as unsolved difficulties. To overcome these unmet needs, a bispecific antibody mimicking activated FVIII has been developed in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rth2.12337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292667PMC

Corrigendum: Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme.

Front Immunol 2020 29;11:934. Epub 2020 May 29.

Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, China.

[This corrects the article DOI: 10.3389/fimmu.2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.00934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274194PMC

Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.

J Thromb Haemost 2020 Jun 11. Epub 2020 Jun 11.

Hematology Department, Hospital Universitario La Paz, Madrid, Spain.

COVID-19 can be associated with coagulopathy (CAC, COVID-19-associated coagulopathy) with a high prothrombotic risk based on an intense inflammatory response to viral infection leading to immunothrombosis through different procoagulant pathways. Emerging evidence suggests that the use of heparin in these patients could be associated with lower mortality. Emicizumab is a bispecific humanized monoclonal antibody that bridges activated factor IX and factor X, thereby restoring the function of missing factor VIIIa in hemophilia A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307111PMC

ETS variant transcription factor 5 and c-Myc cooperate in derepressing the human telomerase gene promoter via composite ETS/E-box motifs.

J Biol Chem 2020 Jul 9;295(29):10062-10075. Epub 2020 Jun 9.

Department of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, USA

The human telomerase gene (hTERT) is repressed in most somatic cells. How transcription factors activate the hTERT promoter in its repressive chromatin environment is unknown. Here, we report that the ETS family protein ETS variant transcription factor 5 (ETV5) mediates epidermal growth factor (EGF)-induced hTERT expression in MCF10A cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.RA119.012130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380182PMC

Edoxaban's contribution to key endothelial cell functions.

Biochem Pharmacol 2020 Aug 31;178:114063. Epub 2020 May 31.

Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain; CIBERCV, Madrid, Spain. Electronic address:

Background: We aimed to study the effects of the new oral anticoagulant edoxaban, a factor X activated (FXa) inhibitor, on key endothelial functions that could contribute to cardiovascular benefit.

Methods: Human umbilical endothelial cells (HUVEC) were obtained from donated umbilical cords and used to analyse 1) structural functions like cell proliferation, migration, and angiogenesis in appropriate assays; 2) anti-inflammatory reactions as mononuclear cell (PBMC) or platelet adhesion to HUVEC monolayers; and 3) haemostasis control by fibrin formation or plasminogen activator modulation. Key molecular effectors and signalling pathways on each function were explored by profiled protein arrays, mRNA, or protein expression analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2020.114063DOI Listing
August 2020
5.009 Impact Factor

The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients.

Arch Pathol Lab Med 2020 Jun 3. Epub 2020 Jun 3.

From the Institute of Cardiology, Jagiellonian University Medical College and John Paul II Hospital, Kraków, Poland (Drs Ząbczyk and Natorska, Ms Kopytek, and Dr Undas); and the Faculty of Health Sciences, Jagiellonian University Medical College, Kraków, Poland (Mr Malinowski).

Context.—: Direct oral anticoagulants (DOACs) may cause falsely negative results of antithrombin (AT) deficiency screening.

Objective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2020-0021-OADOI Listing

In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.

Molecules 2020 May 29;25(11). Epub 2020 May 29.

Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

The coronavirus disease, COVID-19, caused by the novel coronavirus SARS-CoV-2, which first emerged in Wuhan, China and was made known to the World in December 2019 turned into a pandemic causing more than 126,124 deaths worldwide up to April 16th, 2020. It has 79.5% sequence identity with SARS-CoV-1 and the same strategy for host cell invasion through the ACE-2 surface protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules25112529DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321236PMC
May 2020
2.416 Impact Factor

A prospective observational study of acute traumatic coagulopathy in traumatic bleeding from the battlefield.

Transfusion 2020 Jun 1;60 Suppl 3:S52-S61. Epub 2020 Jun 1.

St Thomas' Hospital, Thrombosis & Haemophilia Centre & Thrombosis and Vascular Biology Group, London, UK.

Background: Acute trauma coagulopathy (ATC) after military trauma has not been comprehensively studied. ATC is defined as a prolonged prothrombin time ratio (PTr) or reduced clot amplitude (A5) in viscoelastic testing. Compared to civilian trauma, military trauma has more injuries from explosions and gunshot wounds (GSWs), potentially leading to a different pathophysiology for traumatic coagulopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15658DOI Listing

Serum proteomics analysis of feline mammary carcinoma based on label-free and PRM techniques.

J Vet Sci 2020 May;21(3):e45

College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing 163319, China.

Background: Feline mammary carcinoma is the third most common cancer that affects female cats.

Objectives: The purpose of this study was to screen differential serum proteins in feline and clarify the relationship between them and the occurrence of feline mammary carcinoma.

Methods: Chinese pastoral cats were used as experimental animals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4142/jvs.2020.21.e45DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263907PMC

Laboratory issues in gene therapy and emicizumab.

Haemophilia 2020 May 29. Epub 2020 May 29.

Colorado Coagulation, Laboratory Corporation of America® Holdings, Englewood, CO, USA.

The treatment options for the haemostatic disorders, haemophilia A and haemophilia B, have progressed rapidly over the last decade. The introduction of extended half-life recombinant factor VIII (FVIII) and factor IX (FIX) concentrates to replace these missing clotting factors highlighted discordance between one-stage activated partial thromboplastin time (APTT)-based clotting factor assays and chromogenic factor assays with some products. This raised awareness of the importance of investigation of potential reagent or assay differences by pharmaceutical companies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.13976DOI Listing

Factor X deficiency and pregnancy: case report and counselling.

Haemophilia 2020 May;26(3):e148-e150

Hematology Department, Hospital Israelita Albert Einstein, São Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.12506DOI Listing

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.

J Manag Care Spec Pharm 2020 May 26:1-12. Epub 2020 May 26.

CHOC Children's Hospital, Orange, California.

Background: Hemophilia A (HA) can result in bleeding events because of low or absent clotting factor VIII (FVIII). Prophylactic treatment for severe HA includes replacement FVIII infusions and emicizumab, a bispecific factor IXa- and factor X-directed antibody.

Objective: To develop an economic model to predict the short- and long-term clinical and economic outcomes of prophylaxis with emicizumab versus short-acting recombinant FVIII among persons with HA in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2020.19406DOI Listing

Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data.

Clin Chem Lab Med 2020 May 22. Epub 2020 May 22.

External Quality Control for Assays and Tests (ECAT) Foundation, Voorschoten, The Netherlands.

Objectives Chromogenic anti-activated factor X (FXa) assays are currently the "gold standard" for monitoring indirect anticoagulants. However, anti-FXa has been shown to vary according to the choice of reagents. In the present study, the performance of anti-FXa measurement was evaluated in order to gain more insight into the clinical applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2020-0130DOI Listing

Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.

J Thromb Haemost 2020 Aug 25;18(8):1934-1939. Epub 2020 Jun 25.

Bioscience Research Group, Grifols, Raleigh, NC, USA.

Background: Emicizumab is an alternative non-factor approach for treating patients with hemophilia A. However, there is a potential risk of thrombotic events when emicizumab is concomitantly administered with pro-hemostatic therapies.

Objectives: To assess the hemostatic effect in vitro when a plasma-derived factor VIII concentrate containing von Willebrand factor (pdFVIII/VWF) was added to hemophilia A plasma (HAp) in combination with emicizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14887DOI Listing

"I have been refused to be treated by three dentists": Barriers to patient care.

Spec Care Dentist 2020 May 1;40(3):308-314. Epub 2020 May 1.

Department of Preventive Dentistry, Faculty of Dentistry, Umm Al-Qura University, Makkah, Saudi Arabia.

Background: Factor X deficiency (known as; Stuart-Prower factor deficiency or F10 deficiency) is a rare inherited bleeding disorder. It affects one per 1 million individuals worldwide. Patients with inherited bleeding disorder reported difficulty in accessing primary dental care either due to their medical diseases or their related barriers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/scd.12463DOI Listing

Spontaneous rupture and hematoma of the sartorius muscle secondary to rivaroxaban therapy.

J Surg Case Rep 2020 Apr 24;2020(4):rjaa090. Epub 2020 Apr 24.

Cardiología Intervencionista, Hospital Centro Médico, Guatemala, Guatemala.

Spontaneous muscular hematomas are quite rare as they occur mush less frequently than intracranial hematomas and gastrointestinal bleeding in patients under oral anticoagulant therapy. Coumarins, such as warfarin or acitrom, are the most widely prescribed oral anticoagulants agents and have been associated more with the development of hematomas than direct factor X inhibitors, such as rivaroxaban [ 1]. Few reports have linked oral anticoagulation therapy with the development of muscular hematomas; however, clinical cases regarding the involvement of the sartorius muscle remain limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jscr/rjaa090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180321PMC

Is It Truly "Alpha"? Incidence of Thrombotic Events With Andexanet Alfa at a Single Academic Medical Center.

Ann Emerg Med 2020 05;75(5):675-676

Department of Pharmacy, Upstate University Hospital, Syracuse, NY; Department of Medicine, Upstate Medical University, Syracuse, NY; Upstate Pharmacy Services Translational Research Team (UPSTART).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annemergmed.2019.12.026DOI Listing

Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.

Int J Lab Hematol 2020 06;42 Suppl 1:19-20

Department of Clinical Chemistry and Laboratory Medicine, University Medical Center Utrecht and University Utrecht, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.13230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264532PMC

Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.

Haemophilia 2020 Jul 20;26(4):631-636. Epub 2020 Apr 20.

The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania.

Introduction: Emicizumab is a recombinant humanized bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of factor VIII. It is approved to prevent bleeding in patients with haemophilia A (HA). Outside of clinical trials, there is limited data on outcomes of patients treated with emicizumab, particularly in children without inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.14005DOI Listing

The cellular prion protein is a stress protein secreted by renal tubular cells and a urinary marker of kidney injury.

Cell Death Dis 2020 Apr 17;11(4):243. Epub 2020 Apr 17.

INSERM U1138, Centre de Recherche des Cordeliers, INSERM, Sorbonne Université de Paris, F-75006, Paris, France.

Endoplasmic Reticulum (ER) stress underlies the pathogenesis of numerous kidney diseases. A better care of patients with kidney disease involves the identification and validation of ER stress biomarkers in the early stages of kidney disease. For the first time to our knowledge, we demonstrate that the prion protein PrP is secreted in a conventional manner by ER-stressed renal epithelial cell under the control of the transcription factor x-box binding protein 1 (XBP1) and can serve as a sensitive urinary biomarker for detecting tubular ER stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-020-2430-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165184PMC

Molecular mechanism of a novel Ser362Asn mutation causing inherited FX deficiency in a Chinese family.

Int J Hematol 2020 Jul 13;112(1):8-16. Epub 2020 Apr 13.

Department of Hematology, The Second Hospital of Shanxi Medical University, No. 382 Wuyi Road, Taiyuan, 030001, Shanxi, People's Republic of China.

Factor X (FX) deficiency is an inherited autosomal recessive bleeding disorder. Here, we analyzed a proband with FX deficiency in a Chinese family. Genetic analysis revealed that the proband and his affected sister was homozygous for c. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02877-yDOI Listing

Management of epistaxis in patients on novel oral anticoagulation therapy.

J Laryngol Otol 2020 Apr 13;134(4):316-322. Epub 2020 Apr 13.

Department of Otolaryngology Head and Neck Surgery, Westmead Hospital, Australia.

Background: Individuals on anticoagulation therapy are at increased risk of bleeding, including epistaxis. There is a lack of available reversal agents for novel oral anticoagulation therapy.

Objective: This paper reviews the current literature on epistaxis in the context of novel oral anticoagulation use, in order to recommend guidelines on management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S0022215120000754DOI Listing
April 2020
0.700 Impact Factor

ZNF263 is a transcriptional regulator of heparin and heparan sulfate biosynthesis.

Proc Natl Acad Sci U S A 2020 04 10;117(17):9311-9317. Epub 2020 Apr 10.

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093-0687;

Heparin is the most widely prescribed biopharmaceutical in production globally. Its potent anticoagulant activity and safety makes it the drug of choice for preventing deep vein thrombosis and pulmonary embolism. In 2008, adulterated material was introduced into the heparin supply chain, resulting in several hundred deaths and demonstrating the need for alternate sources of heparin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1920880117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196839PMC

Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.

Blood 2020 May;135(22):1969-1982

Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, and.

Anticoagulant protein S (PS) in platelets (PSplt) resembles plasma PS and is released on platelet activation, but its role in thrombosis has not been elucidated. Here we report that inactivation of PSplt expression using the Platelet factor 4 (Pf4)-Cre transgene (Pros1lox/loxPf4-Cre+) in mice promotes thrombus propensity in the vena cava, where shear rates are low, but not in the carotid artery, where shear rates are high. At a low shear rate, PSplt functions as a cofactor for both activated protein C and tissue factor pathway inhibitor, thereby limiting factor X activation and thrombin generation within the growing thrombus and ensuring that highly activated platelets and fibrin remain localized at the injury site. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019003630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256357PMC

A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.

Indian J Nephrol 2020 Mar-Apr;30(2):110-112. Epub 2020 Feb 7.

Department of Nephrology, PGIMER, Chandigarh, India.

Deranged coagulogram is a common problem, which a nephrologist faces before doing a renal biopsy. We describe a rare cause of coagulopathy in a patient with rapidly progressive renal failure due to acquired factor X deficiency caused by systemic light chain amyloidosis (AL). The patient had prolonged prothrombin and activated partial thromboplastin time, which got corrected on mixing with normal plasma, and factor X activity was markedly reduced at 5%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijn.IJN_213_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132846PMC
February 2020

Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.

Haemophilia 2020 May 6;26(3):536-542. Epub 2020 Apr 6.

Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.

Introduction: Emicizumab (Hemlibra, Roche-Chugai) is a recombinant humanized bispecific IgG4 antibody which mimics some of the actions of activated factor VIII (FVIIIa) by binding to factor X (FX) and activated factor IX (FIXa) to activate FX.

Aim: To evaluate the effect of emicizumab on the APTT, standard one-stage APTT-based FVIII activity assay (sOSA) using plasma calibrators, modified OSA (mOSA) using r Diagnostics emicizumab specific calibrator and chromogenic FVIII assays. Tests were performed on plasma artificially spiked with emicizumab and from four severe haemophilia A (SHA) patients treated with emicizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.13990DOI Listing

Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.

Arterioscler Thromb Vasc Biol 2020 05 2;40(5):1148-1154. Epub 2020 Apr 2.

From the Department of Pediatrics (K.Y., K.N.), Nara Medical University, Kashihara, Japan.

Emicizumab is a humanized anti-FIXa/FX (factor IXa/X) bispecific monoclonal antibody that mimics FVIIIa (activated factor VIII) cofactor function. The hemostatic efficacy of emicizumab has been confirmed in clinical studies of patients with hemophilia A, irrespective of the presence of FVIII inhibitors. Emicizumab differs in some properties from FVIIIa molecule. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/ATVBAHA.120.312919DOI Listing

MYC-Associated Factor MAX is a Regulator of the Circadian Clock.

Int J Mol Sci 2020 Mar 26;21(7). Epub 2020 Mar 26.

Molecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), 16135 Genoa, Italy.

The circadian transcriptional network is based on a competition between transcriptional activator and repressor complexes regulating the rhythmic expression of clock-controlled genes. We show here that the MYC-associated factor X, MAX, plays a repressive role in this network and operates through a MYC-independent binding to E-box-containing regulatory regions within the promoters of circadian BMAL1 targets. We further show that this "clock" function of MAX is required for maintaining a proper circadian rhythm and that MAX and BMAL1 contribute to two temporally alternating transcriptional complexes on clock-regulated promoters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21072294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177918PMC

Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease.

Thromb Res 2020 05 14;189:140-146. Epub 2020 Mar 14.

University of Ferrara, Department of Life Sciences and Biotechnology, 44121 Ferrara, Italy.

Background: High plasma levels of activated Factor VII-Antithrombin complex (FVIIa-AT) have been associated with an increased risk of cardiovascular mortality in patients with stable coronary artery disease (CAD).

Objectives: To investigate if FVIIa-AT levels are associated with activated factor X generation (FXaG) in modified assays.

Patients/methods: Forty CAD patients were characterized for FVIIa-AT levels by ELISA and for FXaG in plasma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2020.03.007DOI Listing

Factor X Deficiency Management for Elective Cesarean Delivery in a Pregnant Patient.

Am J Case Rep 2020 Mar 18;21:e920685. Epub 2020 Mar 18.

Department of Anesthesiology, Intensive Care and Pain Medicine, Clinical Hospital Center Rijeka, Rijeka, Croatia.

BACKGROUND Congenital factor X deficiency is a rare inherited coagulopathy. Pregnancies in women with this disorder are often associated with adverse outcomes, including miscarriage, premature labor, and hemorrhage during pregnancy and in the peripartum period. The literature on this disorder is sparse and shows a limited number of successful pregnancies in women with factor X deficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.920685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117852PMC

Fetal subdural hematoma, sickle cell disease and storage pool disease: A case report.

Case Rep Womens Health 2020 Apr 20;26:e00183. Epub 2020 Feb 20.

Department of Obstetrics and Gynecology, University Hospital, University of Duisburg-Essen, Essen, Germany.

A fetal subdural hematoma (SDH) was diagnosed in a patient with sickle cell disease (SCD) during a routine ultrasound exam in the 30th week of pregnancy. A scan performed a few days earlier had revealed no abnormalities. After interdisciplinary consultation with neurosurgeons and neonatologists, a cesarean section was performed since acute subdural bleeding was hypothesized and the mother's condition was critical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.crwh.2020.e00183DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057149PMC

Coagulation factor VIIa binds to herpes simplex virus 1-encoded glycoprotein C forming a factor X-enhanced tenase complex oriented on membranes.

J Thromb Haemost 2020 Jun 9;18(6):1370-1380. Epub 2020 Apr 9.

Center for Innovation, Canadian Blood Services, Vancouver, BC, Canada.

Background: The cell membrane-derived initiators of coagulation, tissue factor (TF) and anionic phospholipid (aPL), are constitutive on the herpes simplex virus type 1 (HSV1) surface, bypassing physiological regulation. TF and aPL accelerate proteolytic activation of factor (F) X to FXa by FVIIa to induce clot formation and cell signaling. Thus, infection in vivo is enhanced by virus surface TF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14790DOI Listing

Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways.

Inflammopharmacology 2020 Mar 5. Epub 2020 Mar 5.

Pharmacology and Toxicology Department, Faculty of Pharmacy, Beni-Suef University, Beni Suef, Egypt.

Activated factor X (FXa) is strongly linked to various inflammatory events. This study aimed to investigate the effect of FXa on janus kinase2/signal transducers and activators of transcription3 (JAK2/STAT3) and mitogen-activated protein kinase (MAPK) phosphorylation in relation to rheumatoid arthritis (RA). It also extends its scope to explore the possible anti-arthritic effects of apixaban, a selective FXa inhibitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10787-020-00693-8DOI Listing

The CARM1-p300-c-Myc-Max (CPCM) transcriptional complex regulates the expression of and affects the stability of CRL4 E3 ligases in colorectal cancer.

Int J Biol Sci 2020 4;16(6):1071-1085. Epub 2020 Feb 4.

Department of Integrated Traditional and Western Medicine, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China.

The transcription factor c-Myc and two cullin family members CUL4A/4B function as oncogenes in colorectal cancer. Our recent publication reveals that c-Myc specifically activates the expression of through binding to their promoters. However, the underlying mechanism of how c-Myc actions in this process is still unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijbs.41230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053342PMC
February 2020